Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of kinsenoside in preparation of medicine for treating radiation hepatic fibrosis

A technology of radioactive liver fibrosis and aureoside, applied in the field of medicine, can solve problems such as poor treatment effect, and achieve the effect of inhibiting radioactive liver fibrosis and reducing the degree of fibrosis

Pending Publication Date: 2021-12-03
HUAZHONG UNIV OF SCI & TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The present invention solves the technical problem of poor therapeutic effect of radioactive liver fibrosis drugs in the prior art. The present invention aims to provide a drug for intervening radioactive liver fibrosis. By constructing a rat model of radioactive liver fibrosis, the golden Clematis can treat radiation-induced liver fibrosis in rats, providing a candidate drug for the clinical prevention and treatment of radiation-induced liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kinsenoside in preparation of medicine for treating radiation hepatic fibrosis
  • Application of kinsenoside in preparation of medicine for treating radiation hepatic fibrosis
  • Application of kinsenoside in preparation of medicine for treating radiation hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Animal level study of auroside intervening radiation-induced liver fibrosis.

[0032] Clematis glucoside powder was provided by the School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology. Sprague-Dawley rats were randomly divided into 4 groups, normal control group, simple administration group, simple irradiation group and auroside administration group after irradiation. The irradiation group was given a single dose of 30Gy irradiation on the right part of the liver, and the administration group was administered with auroside solution (20mg / kg) once a day for a total of 8 weeks. After 24 weeks of irradiation, liver fibers were compared by HE staining, Masson staining, fibrosis score, collagen immunofluorescence detection, hydroxyproline content determination, α-SMA immunohistochemistry, and histoprotein immunoblotting (Western Blot). degree of transformation. In addition, nude mice were inoculated with liver cancer cells a...

Embodiment 2

[0033] Example 2: Study on cell level of auroside intervening radiation-induced liver fibrosis.

[0034] The HSCs were divided into normal control group, simple administration group, simple irradiation group and auroside administration group after irradiation, and the irradiation group was treated with 6Gy rays. α-SMA is an indicator of hepatic stellate cell activation, which means that radiation exposure causes hepatic stellate cells to be activated at the transcriptional level, while auroside administration after irradiation inhibits the activation of this gene. Compared with the simple irradiation group, α-SMA The expression of SMA mRNA decreased and the difference was statistically significant (P Figure 7 in A). The results of protein immunofluorescence showed that, compared with the simple irradiation group, the expression of α-SMA protein in the auroside administration group after irradiation was significantly reduced ( Figure 7 in B). Using transcriptome high-through...

Embodiment 3

[0035] Example 3: Auroside interferes with radiation-induced liver fibrosis through the TGF-β1 / Smad / CTGF pathway.

[0036] TGF-β1 is a key driving factor of fibrosis, it can finally induce fibrosis through a variety of signaling pathways and a variety of cell interactions, CTGF, as a pro-fibrotic stromal cell protein, is located downstream of it and is responsible for the extracellular The final stage of matrix accumulation. Exogenous transforming growth factor-β1 (TGF-β1) was used to treat HSC cells and detect the expression of fibrosis key proteins. The content of activated TGF-β1 in HSC supernatant was detected by enzyme-linked immunosorbent assay (ELISA). Western blotting was used to analyze the expression of TGF-β1 and its downstream pathway proteins after irradiation. The results showed that exogenous TGF-β1 induced HSC to produce CTGF, and at the same time the expression of α-SMA and collagen increased ( Figure 9 in A). After 6Gy irradiation, the secretion of activ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of kinsenoside in preparation of a medicine for treating radiation hepatic fibrosis, and belongs to the technical field of medicines. The kinsenoside is applied to preparation of drugs capable of inhibiting connective tissue growth factors so as to intervene in radiation hepatic fibrosis. Preferably, the radiation hepatic fibrosis is radiation induced hepatic fibrosis; the medicine inhibits the activation of hepatic stellate cells; and the medicine inhibits a signal channel expressed by a transforming growth factor [beta]1 activated after irradiation, a hepatic stellate cell activation marker protein Smad and a connective tissue growth factor CTGF protein. By constructing a radiation hepatic fibrosis rat model, it is proved for the first time that kinsenoside can treat radiation hepatic fibrosis in rats, and candidate drugs are provided for clinical prevention and treatment of radiation hepatic fibrosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to medicines for treating liver diseases, more specifically, to medicines for treating radioactive liver fibrosis, that is, the application of auroside for preparing radioactive liver fibrosis medicines. Background technique [0002] Radiation therapy is one of the important treatments for abdominal malignancies including hepatocellular carcinoma, gastric cancer and malignant lymphoma. However, the radiation damage to normal tissues caused by radiation therapy often restricts the radiation dose and the curative effect of radiation therapy, and the delayed damage to organs accompanied by radiation therapy, such as radiation-induced liver fibrosis (RILF), often Inevitable and even fatal in some cases. Unlike other liver fibrosis, the occurrence of radiation-induced liver fibrosis is closely related to the radiation therapy of liver tumors. Liver cancer is a radiosensitive tumor, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16A61P39/00
CPCA61K31/7048A61P1/16A61P39/00
Inventor 张勇慧袁响林聂晓琦童擎一
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com